Alx oncology to present alx148 clinical data at the esmo 23rd world congress on gastrointestinal cancer

Updated results will be presented from aspen-01, the ongoing phase 1b study of alx148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer updated results will be presented from aspen-01, the ongoing phase 1b study of alx148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer
ALXO Ratings Summary
ALXO Quant Ranking